Clinical trial of cellular immunotherapy for malignant tumor (alpha-beta T cell-based cancer immunotherapy) - Alpha-beta T cell-based cancer immunotherapy

Start Date12 Nov 2012

Sponsor / Collaborator-

100 Clinical Results associated with Alpha-Beta T Cells(Editas)

100 Translational Medicine associated with Alpha-Beta T Cells(Editas)

100 Patents (Medical) associated with Alpha-Beta T Cells(Editas)

Literatures (Medical) associated with Alpha-Beta T Cells(Editas)

27 May 2013·TransplantationQ2 · MEDICINE

Effectiveness of Topical Immunosuppressants in Prevention and Treatment of Rejection in Face Allotransplantation

Q2 · MEDICINE

Article

Author: Antonio Rampazzo ; Maria Zofia Siemionow ; Selman Hakki Altuntas ; Bahar Bassiri Gharb ; Jason Stratton ; Joanna Cwykiel ; Maria Madajka

BACKGROUNDThe use of topical immunosuppressants has been anecdotally reported for the treatment of rejection in vascularized composite allotransplantation. The aim of this study was to evaluate the effectiveness of topical tacrolimus and clobetasol in the prevention and treatment of rejection.METHODSSeventy-six hemiface allotransplants, between ACI (RT1) donors and Lewis (RT1) recipients, were performed in 11 groups and treated with topical tacrolimus or clobetasol, or in combination with systemic cyclosporine A and anti-αβ-T-cell receptor antibody for 1 week. Topical treatment increased the survival of the allograft in all groups.RESULTSBest outcomes were obtained in the groups treated with systemic therapy and topical tacrolimus. Expression of proinflammatory cytokines interleukin 2, interferon γ, tumor necrosis factor α, and transforming growth factor β correlated with clinical signs of rejection and the final outcomes. Clobetasol application was associated with a marked depletion of lymphocytic populations, and dermal and epidermal atrophy.CONCLUSIONSBoth topical tacrolimus and clobetasol were effective in treating episodes of acute rejection, and the best outcomes were achieved when their application was initiated after systemic immunosuppression. Topical tacrolimus proved to be a preferable adjunct agent to the systemic therapy by preventing both the local and systemic complications.

30 Jun 1980·La Clinica terapeutica

[Acute and chronic respiratory effects of an alpha-beta antagonist with antihypertensive action].

Article

Author: Turco, P ; Dal Negro, R

Polish journal of pharmacology

Phorbol ester and central chemosympathectomy augment beta-adrenoceptor response by different mechanisms.

Article

Author: Vetulani, J ; Nalepa, I

The aim of this study was to compare the mechanisms of increased responsiveness of the beta-adrenoceptor dependent cyclic AMP generating system induced by chronic decrease of noradrenaline availability (beta-upregulation) with that resulting from simultaneous stimulation of alpha-adrenoceptors (alpha-potentiation) and to assess the role of protein kinase C in these phenomena. The beta-upregulation was produced by central chemosympathectomy with 6-hydroxydopamine. The role of alpha 1- and alpha 2-adrenoceptors was assessed by comparison of the effects of specific beta-adrenoceptor agonist isoproterenol with those of a mixed alpha-beta-adrenoceptor agonist noradrenaline, and clonidine was used to selectively stimulate alpha 2-adrenoceptors. The role of protein kinase C was assessed by measuring cyclic AMP responses in the presence and absence of 12-O-tetradecanoyl-phorbol 13-acetate. The results indicate that the mechanism of increased responsiveness induced by central chemosympathectomy is different from the alpha-potentiation, that only alpha 1-adrenoceptors are involved positively in alpha-potentiation, while the alpha 2-adrenoceptors play an inhibitory role, and that increased responsiveness following central chemosympathectomy may be inhibited by protein kinase C activation.

100 Deals associated with Alpha-Beta T Cells(Editas)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	IND Application	US	Editas Medicine, Inc.	17 Jun 2024
Neoplasms	IND Application	US	Bristol Myers Squibb Co.	17 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Alpha-Beta T Cells(Editas)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation